Chengda Pharmaceutical Co., Ltd
Initial public offering and listing on GEM
Announcement of issuance results
Sponsor (lead underwriter): Everbright Securities Company Limited(601788)
The application of Chengda Pharmaceutical Co., Ltd. (hereinafter referred to as “Chengda pharmaceutical” or “the issuer”) for initial public offering of no more than 24174035 ordinary shares (A shares) (hereinafter referred to as “this offering”) and listing on the gem has been examined and approved by the GEM Listing Committee of Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”), It has been approved for registration by China Securities Regulatory Commission (zjxk [2021] No. 3857). The sponsor (lead underwriter) of this offering is Everbright Securities Company Limited(601788) (hereinafter referred to as “sponsor (lead underwriter)”). The issuer’s stock is abbreviated as “Chengda pharmaceutical” and the stock code is “301201”.
The issuance adopts directional placement to strategic investors (hereinafter referred to as “strategic placement”) Offline inquiry placement (hereinafter referred to as “offline issuance”) to qualified offline investors and online pricing issuance (hereinafter referred to as “online issuance”) to social public investors holding non restricted A-share shares and market value of non restricted depositary receipts in Shenzhen market.
The issuer and the sponsor (lead underwriter) Everbright Securities Company Limited(601788) (hereinafter referred to as the “sponsor (lead underwriter)”) negotiated and determined that the number of shares issued this time is 24174035 shares, and the issue price is 72.69 yuan / share, It shall not exceed the median and weighted average of offline investors\’ quotations after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund established through public offering after excluding the highest quotation The enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds, whichever is lower.
According to the issuing price, the relevant subsidiaries of the sponsor do not participate in the strategic placement. The strategic placement of this issuance is only the participation of the issuer’s senior managers and core employees in the special asset management plan established by this strategic placement. The final number of strategic placement is 907965 shares, accounting for about 3.76% of the total number of this issuance, The difference between the initial strategic placement and the final strategic placement was 2718140 shares, which were transferred back to offline issuance.
After the strategic placement callback and before the online and offline callback mechanism was launched, the number of offline issuance was 17102070 shares, accounting for 73.51% of the number issued after deducting the final strategic placement; The number of shares issued online was 61640000, accounting for 26.49% of the number issued after deducting the final strategic placement.
According to the callback mechanism announced in the announcement of Chengda Pharmaceutical Co., Ltd. on initial public offering and listing on the gem (hereinafter referred to as the “issuance announcement”), since the initial effective subscription multiple on the Internet is 10254.23816 times, higher than 100 times, the issuer and the sponsor (lead underwriter) decided to start the callback mechanism, After deducting the final strategic placement, 20% of the number of publicly issued shares (rounded up to an integral multiple of 500 shares, i.e. 4653500 shares) will be transferred back online from offline. After the call back, the final number of offline shares issued was 124485700 shares, accounting for 53.51% of the number issued after deducting the final strategic placement; The final number of shares issued online was 10.8175 million, accounting for 46.49% of the number issued after deducting the final strategic placement. After the call back, the winning rate of this online issuance is 0.0171143683%, and the effective subscription multiple is 5843.04359 times.
The online and offline subscription and payment of this offering has been completed on January 12, 2022 (T + 2). The details are as follows:
1、 Statistics on subscription of new shares
According to the data provided by Shenzhen Stock Exchange and Shenzhen Branch of China depository and Clearing Corporation Limited, the sponsor (lead underwriter) has made statistics on the subscription of new shares issued online and offline in this strategic placement. The results are as follows:
(I) strategic placement
The offering price is not higher than the lower of the median and weighted average of offline investors’ quotations after excluding the highest quotation and the median and weighted average of public funds, social security funds, pensions, enterprise annuity funds and insurance funds after excluding the highest quotation. Therefore, relevant subsidiaries of the sponsor need not participate in follow-up investment.
In this offering, the final strategic placement investors are only the senior management and core employees of the issuer to participate in the special asset management plan established by this strategic placement: the employees of Guangzheng asset management Chengda pharmaceutical participate in the collective asset management plan of gem strategic placement.
As of January 4, 2022 (T-4), strategic investors have paid their subscription funds in full and on time. According to the relevant agreements in the strategic placement agreement signed by the issuer, the sponsor (lead underwriter) and the strategic investor, the strategic placement results of this issuance are determined as follows:
Name of strategic investor number of allocated shares allocated amount sales restriction period (10000 shares) (10000 yuan) (month)
Guangzheng asset management Chengda pharmaceutical employees participate in gem 90.7965 6599.997585 12
Strategic placement collective asset management plan
(II) online subscription of new shares
1. Number of shares subscribed by online investors (shares): 10425563
2. Subscription amount paid by online investors (yuan): 757834174.47
3. Number of online investors giving up subscription (shares): 391937
4. Subscription amount waived by online investors (yuan): 28489900.53
(III) offline subscription of new shares
1. Number of shares subscribed by offline investors (shares): 12448570
2. Subscription amount paid by offline investors (yuan): 904886553.30
3. Number of offline investors giving up subscription (shares): 0
4. Subscription amount abandoned by offline investors (yuan): 0
2、 Offline proportional restriction
The offline issuance part adopts the proportional sales restriction method, and the offline investors shall promise that the sales restriction period of 10% (rounded up) of the number of shares allocated to them is 6 months from the date of the issuer’s initial public offering and listing. That is, among the shares allocated to each placing object, 90% of the shares are sold indefinitely and can be circulated from the date when the issued shares are listed and traded on the Shenzhen Stock Exchange; The sales restriction period of 10% of the shares is 6 months, which shall be calculated from the date of listing and trading of the issued shares on the Shenzhen Stock Exchange.
When offline investors participate in the preliminary inquiry and quotation and offline subscription, they do not need to fill in the arrangement of the sales restriction period for the placing objects under their management. Once the quotation is made, it is deemed to accept the arrangement of the online sales restriction period disclosed in this announcement.
In this offering, the number of shares whose offline proportion is restricted for 6 months is 1247381, accounting for about 10.02% of the total offline issuance and 5.16% of the total public offering.
3、 Underwriting by the sponsor (lead underwriter)
All the shares abandoned by online and offline investors are underwritten by the sponsor (lead underwriter). The number of underwritten shares by the sponsor (lead underwriter) is 391937, with an underwritten amount of 28489900.53 yuan. The number of underwritten shares by the sponsor (lead underwriter) accounts for 1.62% of the total issued shares.
On January 14, 2022 (T + 4), the recommendation institution (lead underwriter) will transfer the underwriting funds to the issuer together with the funds raised from strategic placement and online and offline issuance after deducting the recommendation and underwriting fee in accordance with the recommendation and underwriting agreement. The issuer will submit an application for share registration to China Securities Depository and Clearing Co., Ltd. Shenzhen Branch and register the underwritten shares in the securities account designated by the underwriting syndicate.
4、 Contact information of sponsor (lead underwriter)
If online and offline investors have any questions about the issuance results announced in this announcement, please contact the sponsor (lead underwriter) of this issuance. Contact details are as follows:
Sponsor (lead underwriter): Everbright Securities Company Limited(601788)
Tel.: 021-52523076, 52523077
Contact: equity capital market department
Issuer: sponsor (lead underwriter) of Chengda Pharmaceutical Co., Ltd.: Everbright Securities Company Limited(601788) January 14, 2022 (this page has no text and is the seal page of the announcement on the results of initial public offering and listing on the gem of Chengda Pharmaceutical Co., Ltd.)
Issuer: Chengda Pharmaceutical Co., Ltd. (this page has no text and is the seal page of the announcement on the results of initial public offering and listing on the gem of Chengda Pharmaceutical Co., Ltd.)
Sponsor (lead underwriter): Everbright Securities Company Limited(601788) mm / DD / yy
